A Review of the Preclinical Pharmacology of Tiagabine: A Potent and Selective Anticonvulsant GABA Uptake Inhibitor

Epilepsia

Volumn 36, Issue 6, 1995, Pages 612-626

  Suzdak, Peter D ^a   Jansen, Jens Aas ^b  

^a Pharmaceuticals Division ^*  (Denmark)

^b NOVO NORDISK A S   (Denmark)

Author keywords

Anticonvulsants; Drug receptors; Drug toxicity; Epilepsy; GABA receptors; Tiagabine

Indexed keywords

1 (4,4 DIPHENYL 3 BUTENYL)GUVACINE; 2 [4 (2 CARBOXYETHYL)PHENETHYLAMINO]ADENOSINE 5' (N ETHYLCARBOXAMIDE); 3 (5 METHYL 1H IMIDAZOL 4 YL) 1 (1 METHYL 1H INDOL 3 YL) 1 PROPANONE; 4 AMINOBUTYRIC ACID; 4 AMINOBUTYRIC ACID A RECEPTOR; 4 ETHYL 6,7 DIMETHOXY BETA CARBOLINE 3 CARBOXYLIC ACID METHYL ESTER; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; ANTICONVULSIVE AGENT; BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; CLONAZEPAM; DIAZEPAM; DOPAMINE; GLUTAMIC ACID; KETANSERIN; MEPYRAMINE; N SEC BUTYL 1 (2 CHLOROPHENYL) N METHYL 3 ISOQUINOLINECARBOXAMIDE; NALOXONE; NIPECOTIC ACID; NITRENDIPINE; PENTETRAZOLE; PHENOBARBITAL; PHENYTOIN; PIRENZEPINE; PRAZOSIN; SPIPERONE; TIAGABINE; TRITIUM; UNINDEXED DRUG; VALPROIC ACID; VIGABATRIN;

ANALGESIA; ANIMAL MODEL; ANTICONVULSANT ACTIVITY; ANTICONVULSANT THERAPY; ARTICLE; BRAIN ISCHEMIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; EPILEPTOGENESIS; GABAERGIC TRANSMISSION; GRAND MAL EPILEPSY; HUMAN; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; ISOTOPE LABELING; MOUSE; NEUROTOXICITY; NONHUMAN; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RAT; RECEPTOR BINDING; SUBCUTANEOUS DRUG ADMINISTRATION; TRANQUILIZING ACTIVITY;

ANIMALS; ANTICONVULSANTS; BEHAVIOR, ANIMAL; BRAIN ISCHEMIA; DOGS; GAMMA-AMINOBUTYRIC ACID; HUMANS; KINDLING, NEUROLOGIC; MICE; MICE, INBRED DBA; NEUROTRANSMITTER UPTAKE INHIBITORS; NIPECOTIC ACIDS; RATS; RECEPTORS, GABA; SEIZURES; SELF ADMINISTRATION;

EID: 0028999957     PISSN: 00139580     EISSN: 15281167     Source Type: Journal    
DOI: 10.1111/j.1528-1157.1995.tb02576.x     Document Type: Article

References (81)

1. The synthesis of novel GABA uptake inhibitors. 1. Elucidation of the structure‐activity studies leading to the choice of (R)‐1‐[4,4‐bis[3‐methyl‐2‐thienyl)‐3‐butenyl]‐3‐piperidinecarboxylic acid (tiagabine) as an anticonvulsant drug candidate
2. Two different responses of hippocampal pyramidal cells to the application of gamma‐aminobutyric acid
3. GABA receptor agonists: pharmacological spectrum nd therapeutic actions
4. Effect of muscimol, a GABA mimetic agent, on dopamine metabolism in mouse brain
5. Synthesis and metabolic profile of CI‐966: a potent and orally‐active inhibitor of GABA uptake
6. Molecular heterogeneity of the GABA transport system: cloning of two novel high affinity GABA transporters from rat brain
7. GABA‐B receptor pharmacology
8. NO‐328 binds with high affinity to the brain GABA uptake carrier
9. Modulation of GABA receptor interaction with GABA uptake inhibitors
10. Evaluation of anti‐convulsant drugs in DBN2 mice with sound‐induced seizures
11. Excitatory amino acids in epilepsy and novel anti‐epileptic drugs
12. Neurochemical evidence for a nigrotegmental GABAergic projection
13. Functional expression and CNS distribution of a beta‐alanine‐sensitive neuronal GABA transporter
14. Inhibitory postsynaptic currents in rat hippocampal CA1 neurons
15. Tiagabine: phase II study of efficacy and safety in adjunctive treatment of partial seizures
16. Evidence for a GABAergic projection from the substantia nigra to the ventromedial thalamus and to the superior colliculus
17. Biochemical and electrophysiological characteristics of mammalian GABA receptors
18. GABA receptor pharmacology: functional considerations
19. Neuropharmacological and clinical aspects of GABA
20. GABA receptors and their association with benzodiazepine recognition sites
21. GABA
22. Blockade of audiogenic seizures by a GABA‐uptake inhibitor, NO‐328, in the genetically epilepsy‐prone rat
23. The GABA uptake inhibitor tiagabine increases extracellular brain levels of GABA in awake rats
24. Experimental evidence for the development of tolerance to anticonvulsant drug effects
25. Tolerance and dependence
26. Tolerance to antiepileptic drugs effects: experimental evidence and clinical significance
27. Role of the substantia nigra in GABA mediated anticonvulsant actions
28. Paradoxicol GABA excitation of nigral dopaminergic cells: indirect mediation through reticulata inhibitory neurons
29. Vigabatrin: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in epilepsy and disorders of motor control
30. Differential effects of iv and ip muscimol on central dopamine metabolism
31. Cloning and expression of a rat GABA transporter
32. Tolerance to the anticonvulsant effects of benzodiazepines
33. Relative anticonvulsant effects of GABAmimetic and GABA modulatory agents
34. Enhancement of GABA neurotransmission after cerebral ischemia in the rat reduces loss of hippocampal CA1 pyramidal cells
35. Tolerance to the cognitive impairing effects, but not the anticonvulsant effects, of NO‐328: a selective GABA uptake inhibitor
36. Photomyoclonic seizures in the baboon, Papio papio
37. GABA synaptic mechanisms: stereochemical and conformational requirements
38. GABA up‐take inhibitors, relevance to antiepileptic drug research
39. Inhibition of GABA uptake in rat brain slices by nipecotic acid, various isoxazoles and related compounds
40. Antiepileptic drug development program: a co‐operative effort of government and industry
41. Ion dependency of uptake and release of GABA and (RS)‐nipecotic acid studied in cultured mouse cortex neurons
42. GABA‐A receptor phosphorylation: multiple sites, actions and artifacts
43. Molecular characterization of four pharmacologically distinct GABA transporters from mouse brain
44. Psychopharmacology of GABAergic drugs
45. Kindling as a model of drug‐resistant partial epilepsy: selection of phenytoin‐resistant and nonresistant rats
46. Which animal models should be used in the search for new antiepileptic drugs? A proposal based on experimental and clinical considerations
47. GABAmimetics in animal models of seizure states
48. Anticonvulsant and proconvulsant effects of inhibitors of GABA degradation in the amygdala‐kindling model
49. Dynamic interactions of brain neurotransmitter amino acids during limbic seizures
50. Function and pharmacology of multiple GABA‐A receptor subunits
51. Tolerance to the anticonvulsant effects of carbamazepine, diazepam and sodium valproate in kindled rats
52. Photogenic seizures in baboon
53. Anxiolytic effect of NO‐328, a GABA uptake inhibitor
54. Antagonism of the amphetamine cue by both classical and atypical antipsychotic drugs
55. Characterization of tiagabine (NO‐328), a new potent and selective GABA uptake inhibitor
56. Anticonvulsant tolerance and recovery during repeated administration of the GABA uptake inhibitor NO‐328
57. Inhibitory GABAergic nerve terminals decrease at sites of focal epilepsy
58. The effect of two lipophilic GABA uptake blockers in CAI of the rat hippocampal slice
59. The efficacy and safety of new antiepileptic drugs
60. Safety and efficacy of tiagabine as adjunctive treatment for complex partial seizures
61. Comparison of the effect of the GABA uptake blockers tiagabine and nipecotic acid on inhibitory synaptic efficacy in hippocampal CA1 neurons
62. Studies on GABA transport in cobalt experimental epilepsy in the rat
63. Safety and efficacy of three dose levels of tiagabine HCl versus placebo as adjunctive treatment for complex partial seizures
64. Pharmacology of vigabatrin
65. GABA up‐take inhibitors as anticonvulsants
66. The GABA‐A receptor‐gated ion channel: biochemical and pharmacological studies of structure and function
67. Audiogenic seizures in mice
68. Analgesic effect of the GABA uptake inhibitor NO‐328
69. Anatomical and physiological properties of GABAergic neurotransmission in organotypic slice cultures of rat hippocampus
70. Lack of anticonvulsant tolerance following chronic (21 day) treatment with tiagabine
71. Quantitative receptor autoradiography of 3H‐tiagabine (NO‐328) binding to the central GABA uptake carrier
72. NNC‐711, a novel potent and selective GABA uptake inhibitor: pharmacological characterization
73. In‐vivo labeling of the central GABA uptake inhibitor with 3H‐tiagabine
74. Intravenous self‐admin‐istration of the short‐acting benzodiazepine midazolam in the rat
75. Effects of the GABA uptake blocker tiagabine on inhibitory synaptic potentials in rat hippocampal slice cultures
76. GABA neurotransmitter activity in human epileptogenic brain
77. Novel inhibitors of GABA uptake: anticonvulsant actions in rats and mice
78. Pharmacological significance of the structural heterogeneity of the GABA‐A receptor‐chloride ion channel complex
79. Abuse liability of benzodiazepines
80. Biphasic effects of GABA mimetics and antagonists on haloperidol induced catalepsy